Zanidatamab exhibits ‘promising’ efficacy in advanced HER2-positive biliary tract cancer

Jun 1, 2024 | Oncology

Zanidatamab exhibited durable antitumor activity among patients with previously treated advanced HER2-amplified biliary tract cancer, according to results of the phase 2B HERIZON-BTC-01 study presented at ASCO Annual Meeting.

Learn More

Archives

The expanding role of immunotherapy in HCC
TACE-Based Treatment Combinations Effective Against Intermediate-Stage Liver Cancer
Where Is the Future of Adjuvant Therapy for Hepatocellular Carcinoma?
This Radiation Therapy Outperformed TACE in Liver Cancer
Adjuvant chemoradiation combined with immunotherapy for patients with high-risk resectable extrahepatic cholangiocarcinoma and gallbladder cancer: A phase II, multicenter, randomized controlled trial (ACCORD trial)